CMS Decision To Conduct Provenge NCA Could Be "Chilling To Future Innovation," BIO's Greenwood Says
This article was originally published in The Pink Sheet Daily
BIO CEO Jim Greenwood discusses his views on the Medicare national coverage analysis for Dendreon's prostate cancer immunotherapy Provenge with "The Pink Sheet" DAILY.
You may also be interested in...
Dendreon gave an update on the launch of the prostate cancer vaccine during its earnings call on Aug. 3.
Dendreon has already provided the Centers for Medicare and Medicaid Services with extensive information on its new prostate cancer vaccine Provenge (sipuleucel-T), so a lengthy Medicare national coverage analysis is not needed, the firm maintained in July 27 comments to the agency
The Centers for Medicare and Medicaid Services may consider setting formal parameters around Medicare coverage for Dendreon's ground-breaking prostate cancer vaccine Provenge next year.